• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

    6/26/25 7:33:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANRO alert in real time by email

    – Demonstrated target engagement and response prediction for ALTO-203 by theta/beta ratio, a commonly used EEG index of cortical arousal and attentional control –

    – ALTO-203, a non-stimulant compound which demonstrated pro-cognitive and wake-promoting effects, has the potential to address sustained attention abnormalities in EEG biomarker characterized patients –

    – Pharmacodynamic activity is aligned with the proposed mechanism of ALTO-203; improvements in attention and corresponding reductions in EEG theta/beta ratio, as well as response prediction biomarker replicate Phase 1 study findings –

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the identification of a patient selection biomarker and positive pharmacodynamic results from its exploratory Phase 2 proof-of-concept (POC) trial of ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. ALTO-203 is a novel, oral, histamine H3 inverse agonist, designed to modulate circuits underlying cognition, wakefulness, and alertness.

    The profile exhibited by ALTO-203 in the exploratory POC trial demonstrated clear effects on objective measures of attention and wakefulness, with observed improvements linked to changes in the EEG theta/beta ratio—a biomarker indexing cortical arousal and attentional control. These findings replicate results from the Phase 1 study in healthy volunteers, where ALTO-203 treatment led to improvements in sustained attention and reductions in the EEG theta/beta ratio. Baseline EEG theta/beta ratio predicted attentional benefits of ALTO-203 in both the Phase 1 study and Phase 2 POC trial.

    "We aim to leverage objective biomarkers to enable targeted neuropsychiatric drug development so that patients can get better, faster," said Amit Etkin, M.D., Ph.D., founder and CEO of Alto Neuroscience. "In this exploratory trial, we identified a robust biomarker for ALTO-203, EEG high-theta/beta ratio, which is a well-validated measure of abnormal cortical arousal and poor attentional control. Notably, this biomarker is FDA-cleared for use alongside clinical evaluation in the diagnosis of ADHD, reinforcing its clinical relevance. These positive results replicate findings from an ALTO-203 Phase 1 study and enhance our understanding of the patient subtypes most likely to benefit from the drug, further strengthening the foundation of our precision psychiatry approach. We believe our platform has the potential to enable data-driven indication selection and trial design early in development—accelerating the path to more effective, personalized treatment."

    The exploratory Phase 2 POC trial, which enrolled 69 patients, was conducted in two sequential, double-blind, placebo-controlled periods. The trial was designed to characterize the pharmacodynamic, pharmacokinetic, safety, and tolerability profile of ALTO-203 across two dose levels compared to placebo in a crossover design and was not powered to detect statistical significance on traditional depression outcome scales (e.g., MADRS).

    Adam Savitz, M.D., Ph.D., Chief Medical Officer of Alto Neuroscience, commented, "We are encouraged by the positive pharmacodynamic activity observed in the study, which aligns with the proposed mechanism of ALTO-203. The wake-promoting and pro-cognitive effects demonstrated, suggest clear potential for ALTO-203 to be a meaningful treatment across various neuropsychiatric conditions in which sleep and attention are significantly impaired."

    Topline, prespecified results from the exploratory Phase 2 POC trial of ALTO-203 include:

    • Subjective Effects on Bond & Lader Visual Analog Scale (BL-VAS): Patients reported significant improvements from baseline on BL-VAS for alertness & mood at the 5-hour timepoint post dosing with ALTO-203. A higher-than-expected placebo response was observed on the Bond & Lader measurements – no significant separation between ALTO-203 and placebo was observed.
    • EEG Biomarker of Drug Effect Identified: The theta/beta ratio, a neurophysiological marker linked to attentional control, was confirmed as a key pharmacodynamic readout. The effects of ALTO-203 on reducing theta/beta ratio were significant compared to placebo (25µg: p<0.05).
      • This marker was previously shown to be significantly reduced by ALTO-203 in the completed Phase 1 study in healthy subjects, as well as in preclinical studies.
    • Cognitive Enhancement Observed: ALTO-203 treatment led to significant improvements in sustained attention (25µg: p<0.05; 75µg: p=0.06 vs. placebo), aligning with reductions in the EEG theta/beta ratio. Improvement in attention was greatest in patients with high baseline theta/beta ratios (i.e., more abnormal) (25µg: p<0.01; 75µg: p<0.05 vs. placebo).
      • The observed improvements in attention and corresponding changes in EEG theta/beta ratio replicated significant findings from the Phase 1 study.
    • Wearable Device Confirmation: Objective sleep measures from wearable devices supported the wake-promoting effects of ALTO-203, and the increased wakefulness exhibited by ALTO-203 was significant for both doses (25µg: p<0.05; 75µg: p<0.001 vs. placebo).
    • Pharmacokinetics and Safety: ALTO-203 displayed predictable accumulation over multiple doses with no adverse pharmacokinetic signals. ALTO-203 was well tolerated, with insomnia as the most frequent adverse event, consistent with its wake-promoting profile.
    • MADRS Improvements: Patients taking 25µg of ALTO-203 exhibited a mean improvement of 2 points at week 3 and 0.9 points at week 4 compared to placebo. The differences were not observed in the 75µg dose group.
      • MADRS improvements were evaluated during the 28-day multi-dose period, which was not powered to detect significance.

    Alto plans to report additional results from this exploratory study at a future medical meeting and expects to determine the next development steps for ALTO-203 following the complete analysis of the data set.

    About the Phase 2 POC Trial of ALTO-203

    The Phase 2 POC trial enrolled 69 MDD patients with higher levels of anhedonia consisted of two dosing periods (63 completed the primary single-dose period):

    • Single-dose period: Patients received two single-doses of ALTO-203 (25µg and 75µg), and placebo in a randomized, three-way crossover design. The powered primary outcome was an acute change in positive emotion assessed by the alertness and mood components of the Bond-Lader Visual Analog Scale (BL-VAS), an established scale of subjective feelings. Key pre-specified exploratory outcomes included measures of cognition, EEG changes, and effects on sleep.
    • Multi-dose period: Patients were randomized to receive daily administration of ALTO-203 (25µg or 75µg QD) or placebo over 28 days. This period was designed to evaluate extended safety, tolerability, and pharmacokinetics, as well as exploratory biomarkers across EEG, cognitive testing, and wearable device data.

    About Alto Neuroscience

    Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto's clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

    Forward-Looking Statements

    This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "expects," "plans," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto's expectations about the potential benefits, activity, effectiveness and safety of its product candidates and Precision Psychiatry Platform ("Platform"); the reproducibility of any favorable results seen in the exploratory Phase 2 POC trial of ALTO-203 in major depressive disorder; and Alto's expectations with regard to the design and results of its clinical trials. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the initiation, progress and completion of clinical trials and other important factors, any of which could cause Alto's actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled "Risk Factors" in Alto's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.

    Availability of Information on Alto's Website

    Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250626096968/en/

    Investor and Media Contact:

    Mari Purpura

    [email protected]

    [email protected]

    Get the next $ANRO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ANRO

    DatePrice TargetRatingAnalyst
    10/23/2024$29.00 → $4.00Outperform → Neutral
    Wedbush
    10/23/2024Buy → Neutral
    Rodman & Renshaw
    9/3/2024$29.00Outperform
    Wedbush
    2/27/2024Outperform
    William Blair
    2/27/2024Outperform
    TD Cowen
    2/27/2024$32.00Outperform
    Robert W. Baird
    2/27/2024$33.00Buy
    Jefferies
    2/27/2024$32.00Buy
    Stifel
    More analyst ratings

    $ANRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alto Neuroscience downgraded by Wedbush with a new price target

      Wedbush downgraded Alto Neuroscience from Outperform to Neutral and set a new price target of $4.00 from $29.00 previously

      10/23/24 7:37:30 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience downgraded by Rodman & Renshaw

      Rodman & Renshaw downgraded Alto Neuroscience from Buy to Neutral

      10/23/24 6:52:50 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Alto Neuroscience with a new price target

      Wedbush initiated coverage of Alto Neuroscience with a rating of Outperform and set a new price target of $29.00

      9/3/24 7:41:31 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Savitz Adam bought $190,833 worth of shares (15,000 units at $12.72) (SEC Form 4)

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      7/11/24 4:15:04 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smith Nicholas Conrad bought $100,628 worth of shares (6,150 units at $16.36), increasing direct ownership by 30% to 26,866 units (SEC Form 4)

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      4/1/24 4:15:30 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Alto Neuroscience Inc.

      SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

      7/16/25 7:02:16 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience Inc. filed SEC Form 8-K: Leadership Update

      8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

      7/8/25 5:18:54 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

      6/26/25 7:40:43 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CHIEF OPERATING OFFICER Hanley Jr. Michael Conick

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      7/8/25 5:22:49 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF MEDICAL OFFICER Savitz Adam

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      7/8/25 5:22:02 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT AND CEO Etkin Amit

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      7/8/25 5:21:22 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

      –  Compelling PAX-D results guided Alto's acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – –  Alto plans to collaborate with National Health Service, PAX-D clinical sites for the planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study; trial expected to initiate by mid-2026 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-r

      6/30/25 8:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

      – Demonstrated target engagement and response prediction for ALTO-203 by theta/beta ratio, a commonly used EEG index of cortical arousal and attentional control – – ALTO-203, a non-stimulant compound which demonstrated pro-cognitive and wake-promoting effects, has the potential to address sustained attention abnormalities in EEG biomarker characterized patients – – Pharmacodynamic activity is aligned with the proposed mechanism of ALTO-203; improvements in attention and corresponding reductions in EEG theta/beta ratio, as well as response prediction biomarker replicate Phase 1 study findings – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focu

      6/26/25 7:33:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

      – ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

      6/3/25 6:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Christopher Nixon Cox Named Chairman of High-Trend International Group

      SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

      3/13/25 9:00:00 AM ET
      $ANRO
      $HTCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Marine Transportation
      Consumer Discretionary
    • Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

      – Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder and schizophrenia – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto's COO, M

      5/21/24 8:05:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors

      – Experienced Medical and Executive Leader, Dr. Radhakrishnan served as Group SVP and Chief Medical Officer of Biogen, responsible for the Worldwide Medical function – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company's board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies. "Maha joins our Board at a pivotal moment for Alto, as we continu

      3/11/24 8:05:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Financials

    Live finance-specific insights

    See more
    • Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

      –  Compelling PAX-D results guided Alto's acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – –  Alto plans to collaborate with National Health Service, PAX-D clinical sites for the planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study; trial expected to initiate by mid-2026 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-r

      6/30/25 8:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

      – ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

      6/3/25 6:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alto Neuroscience Inc.

      SC 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/14/24 5:46:11 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alto Neuroscience Inc.

      SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/14/24 7:00:29 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alto Neuroscience Inc.

      SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/12/24 9:50:14 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care